1. Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies. Issue 2 (2nd September 2021) Authors: Akizawa, Tadao; Nangaku, Masaomi; Yamaguchi, Takuhiro; Koretomo, Ryosuke; Maeda, Kazuo; Yamada, Osamu; Hirakata, Hideki Journal: Therapeutic apheresis and dialysis Issue: Volume 26:Issue 2(2022) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ‐951), an Oral Erythropoiesis‐Stimulating Agent, in Healthy Adults. Issue 8 (23rd June 2021) Authors: Pai, Sudhakar M.; Yamada, Hiroyuki; Kleiman, Robert B.; Zhuo, Rui; Huang, Qingtao (Mike); Koretomo, Ryosuke Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 8(2021) Page Start: 884 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Mass Balance Study of 14C‐Labeled JTZ‐951 (Enarodustat), a Novel Orally Available Erythropoiesis‐Stimulating Agent, in Patients With End‐Stage Renal Disease on Hemodialysis. Issue 6 (25th December 2019) Authors: Pai, Sudhakar M.; Connaire, Jeffrey; Yamada, Hiroyuki; Enya, Seiji; Gerhardt, Barbara; Maekawa, Michihide; Tanaka, Hiromasa; Koretomo, Ryosuke; Ishikawa, Tomohiro Journal: Clinical pharmacology in drug development Issue: Volume 9:Issue 6(2020) Page Start: 728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗